AbbVie atogepant meets all endpoints in menstrual migraine Phase 3 trial

September 10, 2026 8:55 AM

AbbVie (NYSE: ABBV) announced positive topline results from its Phase 3 LUNA study evaluating atogepant for the preventive treatment of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found